RETRACTION

Open Access Full Text Article

ZFASI Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma [Retraction]

Wang X, Hao R, Wang F, Wang F. Cancer Manag Res. 2020;12:7251-7262.

We, the Editors and Publisher of Cancer Management and Research, have retracted the published article.

Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from figures within the article and with those from other articles. Specifically,

- The western blot bands in Figures 3K, CAL-27/DDP, Bax; SCC-9/DDP, BCL2 and 4C, CAL-27/DDP, β-actin, appear to have been duplicated with those from Figure 6A, Tca8113-CDDP, SF1; Figure 4G, Tca8113-CDDP, BCL2 and Figure 4H, TSCCA-CDDP, β-actin, respectively, from Fang Z, Zhao J, Xie W, Sun Q, Wang H, Qiao B. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. *Cancer Med*. 2017;6:2897–2908. <u>https://doi.org/10.1002/cam4.1253</u>
- The western blot bands in Figure 3K, CAL-27/DDP, β -actin and SCC-9/DDP, β -actin appear to have been duplicated.

When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

https://doi.org/10.2147/CMAR.S432675

Received: 27 July 2023 Accepted: 27 July 2023 Published: 31 July 2023 Cancer Management and Research 2023:15 787

© 1023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of the work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

787